Effects of Systemic Peroxisome Proliferator-Activated Receptor Gamma Inhibition on Bone and Immune Cells in Aged Female Mice

This study investigates the effects of peroxisome proliferator-activated receptor gamma (PPAR gamma) inhibition on bone and immune cell profiles in aged female mice, as well as in vitro stromal stem cell osteogenic differentiation and inflammation gene expression. The hypothesis was that inhibition of PPAR gamma would increase bone mass and alter immune and other cellular functions. Our results showed that treatment with PPAR gamma antagonist GW9662 for 6 weeks reduced bone volume and trabecular number and increased trabecular spacing. However, inhibition of PPAR gamma had no significant effect on marrow and spleen immune cell composition in aged female mice. In vitro experiments indicated that GW9662 treatment increased the expression of osteogenic genes but did not affect adipogenic genes. Additionally, GW9662 treatment decreased the expression of several inflammation-related genes. Overall, these findings suggest that PPAR gamma inhibition may have adverse effects on bone in aged female mice.

Automated summary

This study investigates the effects of PPAR-γ inhibition on bone and immune cell profiles in aged female mice. The results suggest that PPAR-γ inhibition may have adverse effects on bone mass, but does not significantly affect immune cell composition.